INTRODUCTION
Eosinophilic fasciitis (EF) is a rare subtype of deep morphea characterized by progressive symmetric sclerosis of the fascia of the distal extremities with or without truncal involvement.1 Joint contractures, myalgias, and reduced mobility are potential complications.2,3 While oral corticosteroids remain first-line, almost half of EF patients require other immunosuppressants due to incomplete response or treatment intolerance.3,4 The use of intravenous immunoglobulin (IVIG) in addition to standard immunosuppressive treatments has been described in a small retrospective cohort study and a few case reports, which reported IVIG treatment responses in adult patients with recalcitrant EF.4-6 This retrospective observational study describes patient- and physician-reported cutaneous and functional outcomes for adults with EF treated with IVIG at a tertiary referral center.
MATERIALS AND METHODS
This IRB-approved study is a retrospective chart review of all adult patients with EF seen within the University of California San Francisco School of Medicine (UCSF) Department of Dermatology from 1/1/2015 to 6/13/2022. Patients with morphea were identified via a search of ICD-10 billing codes: morphea (L94.0) and eosinophilic fasciitis (M35.4). Authors B.O., W.F., and J.G. reviewed electronic health records to assess for clinical diagnosis of morphea. Author A.H. validated cases of diagnostic uncertainty. Data on demographics, morphea subtype, disease characteristics, treatment course, and response were reviewed. Patients were classified as complete responders, partial responders, or non-responders based on erythema and/or induration (resolved, decreased, or increased, respectively), new or expanding lesions (absent, absent, and present, respectively), functional impairment (significantly
